Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NervGen Pharma Corp. (V:NGEN)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for NGEN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Aug 02, 2022 08:30 ET
NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conference
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer's disease clinical trial at the 2022 Alzheimer's Association International Conference (AAIC) on August 3, 2022. NervGen's Chief Medical Officer, Dr. Daniel Mikol, will present a poster summarizing unblinded data from the single ascending dose (SAD) cohort of the study and interim blinded data from the multiple ascending dose (MAD) portion of the study, and for the first time will introduce the study design for the upcoming Phase 1b/2a trial of NervGen's lead drug candidate, NVG-291, in subjects with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.51
--
--
Price to Sales - TTM
--
10.42
4.38
Price to Book - most recent quarter
9.50
2.19
1.81
Price to Cash Flow per share - TTM
--
10.48
8.71
Price to Free Cash Flow per share - TTM
--
50.89
20.67
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 31, 2022148,797141,177
Jul 15, 20227,620-4,551
Jun 30, 202212,171-13,796
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer's disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.

See business summary

 

Twitter

Search (past week) for $NGEN.CA NGEN.V